Back to top
more

BIOMEA FUSION (BMEA)

(Real Time Quote from BATS)

$1.59 USD

1.59
1,060,128

+0.02 (1.27%)

Updated Aug 4, 2025 09:42 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Biomea Fusion (BMEA) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Biomea Fusion (BMEA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

After Plunging -27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)

by Zacks Equity Research

Biomea Fusion (BMEA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Equity Research

After Plunging -19.32% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)

by Zacks Equity Research

Biomea Fusion (BMEA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Equity Research

After Plunging -20.42% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Biomea Fusion (BMEA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

BMEA Stock Up 9% as FDA Lifts Clinical Hold on 2 Diabetes Studies

by Zacks Equity Research

Biomea stock rises 9% after the FDA lifts clinical hold on two phase I/II studies evaluating the company's lead candidate, BMF-219, for diabetes.

Zacks Equity Research

Wall Street Analysts Think Biomea Fusion (BMEA) Could Surge 317.86%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 317.9% upside potential for Biomea Fusion (BMEA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Biomea Fusion (BMEA) Stock Surges 41% in a Month: Here's Why

by Zacks Equity Research

Biomea Fusion (BMEA) rises 41% in a month on the back of positive investor expectations regarding the clinical development of its lead candidate, BMF-219, for the type II diabetes indication.

Zacks Equity Research

Biomea (BMEA) Doses First Patient in Leukemia Study, Stock Up

by Zacks Equity Research

Biomea (BMEA) successfully doses the first patient in its phase I study of BMF-500 to treat adult patients with acute leukemia. The company's stock rises 6.7% on the news.

Zacks Equity Research

Is Ayr Wellness Inc. (AYRWF) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Ayr Wellness Inc. (AYRWF) and Biomea Fusion, Inc. (BMEA) have performed compared to their sector so far this year.

Zacks Equity Research

Biomea (BMEA) Up 99% on Upbeat Data From Type II Diabetes Study

by Zacks Equity Research

Preliminary data from an ongoing mid-stage study shows that treatment with Biomea's (BMEA) lead candidate demonstrated a robust glucose-lowering response in patients with type II diabetes.

Zacks Equity Research

Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback

by Zacks Equity Research

Pipelines updates from Viking Therapeutics (VKTX) and Intra-Cellular (ITCI) are the key highlights for the biotech sector.

Zacks Equity Research

Has Aspira Women's Health (AWH) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Aspira (AWH) and Biomea Fusion, Inc. (BMEA) have performed compared to their sector so far this year.

Zacks Equity Research

What Makes Biomea Fusion, Inc. (BMEA) a Good Fit for 'Trend Investing'

by Zacks Equity Research

Biomea Fusion, Inc. (BMEA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks Equity Research

Mirati (MRTX) KRAS Candidate MRTX1133 to Enter Clinical Stage

by Zacks Equity Research

Mirati Therapeutics (MRTX) announces IND clearance for oral KRASG12D selective inhibitor, MRTX1133, by the FDA. It is set to initiate phase I/II study in early 2023.

Zacks Equity Research

Biomea (BMEA) Begins Dosing in Lung Cancer Study, Stock Up

by Zacks Equity Research

Biomea Fusion (BMEA) announces the successful dosing of the first patient in phase I/Ib study of BMF-219 in KRAS mutant solid tumors. Stocks rise 11.69% in response.

Zacks Equity Research

Should You Buy Biomea Fusion (BMEA) Ahead of Earnings?

by Zacks Equity Research

Biomea Fusion (BMEA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.